enGene Therapeutics Inc

enGene Therapeutics Inc(ENGN)のニュースとイベント

$1.680

-0.039 (-2.33%)終値時点

ENGN のニュース

ENGN のイベント

9/8 08:00

enGene CEO Highlights Clinical Progress of detalimogene

"As we move through the second half of 2026, our focus is on maturing regulatory endpoints data from LEGEND's pivotal cohort and our planned engagement with the FDA regarding a BLA filing for detalimogene," said Ron Cooper, President and Chief Executive Officer, enGene. "We believe the clinical profile observed to date, together with detalimogene's potential best-in-class tolerability and straightforward, office-based administration, supports it becoming an important treatment option for urologists and their patients with BCG-unresponsive NMIBC. We are pleased to have cleared the surfactant safety run-in period and are encouraged by the progress of the cohort, which is designed to explore whether we can further enhance efficacy and durability while preserving tolerability and the practical attributes that we believe differentiate detalimogene," added Mr. Cooper. "With a strong balance sheet, we remain focused on disciplined capital allocation to advance the program toward BLA submission and prepare for commercialization."

7/16 08:30

enGene Therapeutics Changes Board Chairman

enGene Therapeutics announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid if approved. Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk non-muscle invasive bladder cancer. LEGEND's cohort consists of 125 patients with high-risk, Bacillus Calmette-Guerin-unresponsive NMIBC with carcinoma in situ. Richard Glickman has served as enGene's Chairman for over 14 years and will be stepping down. Michael Heffernan assumes the role of Chairman of the Board.

6/18 16:30

Major Averages Rebound, Nasdaq Gains 1.91%

The major averages closed broadly higher in a rebound from the prior session's selloff after the Federal Reserve held rates steady but signaled that a rate hike later this year remains possible. Meanwhile, oil prices declined after President Donald Trump signed a memorandum of understanding with Iran's President Masoud Pezeshkian to end the war and open the Straight of Hormuz.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump said Applehaswith Intelto design chipsApple CEO Tim Cookthe company will raise prices on its products to offset increasing memory and storage costsAccenturereportedand narrowed its FY26 earnings guidanceKrogerreportedand reaffirmed its FY26 outlookRumbleannounced a2. WALL STREET CALLS:Aretecoverage of SpaceXwith a Buy rating and Street-high $401 price targetSalesforceto Buy at Monness CrespiIntuitto Hold at StifelenGeneto Underweight at Morgan StanleyBarclaysEnphaseto Equal Weight on data center opportunity3. AROUND THE WEB:SpaceXbankers are preparing a $20B bond offering, Bloomberg reportsVail Resortsis working with takeover-defense bankers, Semafor saysSamsungis seeing a rise in advanced chip production requests from BYD, Google, AMD, Tesla, and other companies as AI demand strains TSMC'scapacity, Nikkei Asia reportsThe U.S. Federal Trade Commission, FTC, has drafted a potential complaint against Amazonover claims the company misled advertisers, Bloomberg reportsCME Groupsued the Commodity Futures Trading Commission over the regulator allowing perpetual futures tied to the price of cryptocurrencies, Bloomberg says4. MOVERS:Butterfly Networkgained after commenting on Midjourney'sSmith & Wesson Brandswas higher afterMarvellwas up after announcing it has shipped overwith Tower SemiconductorNovocurewas lower in New York after announcing its Phase 3 TRIDENT trialLegend Biotechfell after announcing a5. EARNINGS/GUIDANCE:Deluxereaffirmed itsGrace TherapeuticsreportedSagtecprovidedSteel DynamicsprovidedNucorprovided itsINDEXES:The Dow rose 72.15, or 0.14%, to 51,564.70, the Nasdaq gained 496.28, or 1.91%, to 26,517.93, and the S&P 500 advanced 80.48, or 1.08%, to 7,500.58.

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める